Literature DB >> 34737676

HIV self-testing in Ottawa, Canada used by persons at risk for HIV: The GetaKit study.

Patrick O'Byrne1, Alexandra Musten2, Amanda Vandyk1, Nikki Ho1, Lauren Orser1, Marlene Haines1, Vickie Paulin3.   

Abstract

BACKGROUND: The Public Health Agency of Canada estimates that about 87% of persons living with human immunodeficiency virus (HIV) in Canada have been diagnosed, which is well below the Joint United Nations Programme on HIV/AIDS target to have 95% of HIV-positive persons diagnosed. Research has shown that HIV self-testing may help increase such diagnoses, especially among the populations who are most affected by HIV. The objective of the study was to determine the uptake and diagnosis outcomes associated with free HIV self-testing.
METHODS: We developed the first online mailout free HIV self-testing program in Canada and implemented it in Ottawa. This project ran through the website, www.GetaKit.ca. We intended to recruit 150-400 participants over a 6-12-month period, estimating that this number would yield between 0-1 positive test results (expected positivity rate of 0.08%).
RESULTS: Between July 20, 2020 and April 1, 2021, 1,268 people accessed the GetaKit website and verified their eligibility. In total, 600 persons were eligible and 405 ordered an HIV kit. Of those who ordered a kit, 399 completed a baseline survey. Overall, 71% of these participants were members of HIV priority groups. For test results, 228 persons reported test results, with one being positive, for a positivity rate of 0.24% overall and 0.44% of reported results. These rates exceed that normally observed in Ottawa.
CONCLUSION: Self-testing of HIV can be effectively delivered through a website. Such an intervention will also be used by persons with undiagnosed infections and appears to do so at a rate higher than that observed by other means of testing. Self-testing of HIV may therefore help Canada achieve the United Nations 95-95-95 targets.

Entities:  

Keywords:  Canada; GetaKit; Keywords: HIV; Ottawa; priority group; self-test

Year:  2021        PMID: 34737676      PMCID: PMC8525857          DOI: 10.14745/ccdr.v47i10a06

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  13 in total

1.  Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.

Authors:  David Kim; James Quinn; Benjamin Pinsky; Nigam H Shah; Ian Brown
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

2.  Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Authors:  Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham
Journal:  PLoS Med       Date:  2010-04-06       Impact factor: 11.069

3.  The association of previous influenza vaccination and coronavirus disease-2019.

Authors:  Ilan Green; Shai Ashkenazi; Eugene Merzon; Shlomo Vinker; Avivit Golan-Cohen
Journal:  Hum Vaccin Immunother       Date:  2020-12-30       Impact factor: 3.452

4.  Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design.

Authors:  Julia Stowe; Elise Tessier; H Zhao; Rebecca Guy; Berit Muller-Pebody; Maria Zambon; Nick Andrews; Mary Ramsay; Jamie Lopez Bernal
Journal:  Int J Epidemiol       Date:  2021-05-03       Impact factor: 7.196

5.  Validation of self-reported influenza vaccination in the current and prior season.

Authors:  Jennifer P King; Huong Q McLean; Edward A Belongia
Journal:  Influenza Other Respir Viruses       Date:  2018-08-14       Impact factor: 4.380

6.  Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season.

Authors:  Greg G Wolff
Journal:  Vaccine       Date:  2019-10-10       Impact factor: 3.641

7.  Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States.

Authors:  Kelly Huang; Shu-Wen Lin; Wang-Huei Sheng; Chi-Chuan Wang
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

8.  The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature.

Authors:  Marco Del Riccio; Chiara Lorini; Guglielmo Bonaccorsi; John Paget; Saverio Caini
Journal:  Int J Environ Res Public Health       Date:  2020-10-27       Impact factor: 3.390

9.  Risk of symptomatic severe acute respiratory syndrome coronavirus 2 infection not associated with influenza vaccination in the 2019-2020 season.

Authors:  Jennifer P King; Huong Q McLean; Edward A Belongia
Journal:  Influenza Other Respir Viruses       Date:  2021-06-25       Impact factor: 5.606

10.  Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020.

Authors:  Danuta M Skowronski; Macy Zou; Suzana Sabaiduc; Michelle Murti; Romy Olsha; James A Dickinson; Jonathan B Gubbay; Matthew A Croxen; Hugues Charest; Agatha Jassem; Mel Krajden; Nathalie Bastien; Yan Li; Gaston De Serres
Journal:  Euro Surveill       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.